8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2009

Shire plc

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486

(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

________________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.  Other Events

     Shire plc has issued the press release attached hereto as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

                  (d)  Exhibits.  The following exhibit is filed herewith:

99.01                Press Release dated December 11, 2009

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
	Name:	Angus Russell
	Title:	Chief Executive Officer

Dated: December 11, 2009

EXHIBIT INDEX
Number	Description
99.01	Press Release dated December 11, 2009

EX-99.1

	Exhibit 99.01
Press Release
www.shire.com

Director/PDMR Shareholding

December 11, 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”), announces that on December 10, 2009, it was notified by Mr Angus Russell, Chief Executive Officer of the Company, of the exercise, on the same day, ofoptions over 479,024 Shire ordinary shares of 5p (“Shares”). Mr Russell chose to use a net settled cashless exercise facility run by the Company.

Number of Shares under option	Exercise price	Number of Shares received	Number of Shares lapsed
284,024	£3.380	201,538	82,486
195,000	£5.585	101,364	93,636

In addition, the Company was notified by Mr Russell on December 10, 2009 of the sale on the same day of 270,164 Shares at an average sale price of £11.6362.

The Company was also notified by Mr Russell on December 10, 2009 of the exercise on the same day of an award of Stock Appreciation Rights (“SARs”) over 128,542 Shares at an exercise price of £8.645.  This resulted in 33,000 Shares being released, of which 13,881 Shares were sold at an average sale price of £11.6362.

Prior to the above transactions, Mr Russell held 90,331 Shares and 2,000 American Depository Shares (“ADSs”).

Following the above transactions, Mr Russell holds 142,188 Shares and 2,000 ADSs. One ADS is equal to three Shares. He also holds options over 75,736 Shares and awards of Stock Appreciation Rights, Performance Shares and Restricted Shares over 1,155,739 Shares.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

Tatjana May

Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 617 551 9715

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX2